Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-11-07

Clinical Trial Update: A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated BI 1358894 for 8 weeks in adults with post-traumatic stress disorder; results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • BI-1358894

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Post-Traumatic Stress Disorder | Phase 2 | Status: COMPLETED | Results posted: 2024-11-07